Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Molecular Pharmacology
  4. Volume 17, Issue 1
  5. Article
Volume 17, Issue 1
  • ISSN: 1874-4672
  • E-ISSN: 1874-4702
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Brucellosis is an infectious disease caused by different species of bacteria. It is also known as Malta fever, one of the neglected diseases that can cause infection in both animals and humans. Although human-to-human infection is rare, it can spread through the inhalation of airborne agents, and if left untreated, it can lead to serious health complications. In this review, we aim to highlight the pathophysiology, prevention, epidemiology, mitigation, cure, targets for drug development, and vaccine development against human brucellosis. Human brucellosis is mainly caused by consuming unpasteurized milk or dairy products, uncooked meat, and contact with infected animals. Human brucellosis outbreaks are mainly associated with developing and low- to middle-income countries. Brucella is present all over the world, and only some of the regions are at high risk, including Asia, Africa, Eastern Europe, Mexico, South and Central America, the Caribbean, the Mediterranean Basin, and the Middle East. Because of intracellular survival, inhibition of apoptosis, and immune evasion, Brucella can survive and multiply inside the host cell, which can cause chronic disease. By using proteomics approaches, several new drug targets were reported for human brucellosis that can be used for the development of novel drugs. We can also develop an efficient vaccine against human brucellosis by exploring previously reported vaccine candidates against animal brucellosis. The information provided through this review will facilitate research to control and cure human brucellosis and its complicated symptoms.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmp/10.2174/1874467217666230713093802
2023-07-13
2024-11-23

  • From This Site

    /content/journals/cmp/10.2174/1874467217666230713093802
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmp/17/1/CMP-17-E130723218680.html?itemId=/content/journals/cmp/10.2174/1874467217666230713093802&mimeType=html&fmt=ahah

References

  1. SmithJ.A. Brucella Lipopolysaccharide and pathogenicity: The core of the matter.Virulence20189137938210.1080/21505594.2017.139554429144201
     [Google Scholar]
  2. KimH.N. HurM. MoonH.W. ShimH.S. KimH. JiM. YunY.M. KimS.Y. UmJ. LeeY.S. HwangS.D. First case of human brucellosis caused by Brucella melitensis in Korea.Ann. Lab. Med.201636439039210.3343/alm.2016.36.4.39027139618
     [Google Scholar]
  3. Avila-GranadosL.M. Garcia-GonzalezD.G. Zambrano-VaronJ.L. Arenas-GamboaA.M. Brucellosis in colombia: Current status and challenges in the control of an endemic disease.Front. Vet. Sci.2019632110.3389/fvets.2019.0032131616678
     [Google Scholar]
  4. CorbelM.J. Brucellosis in humans and animals.World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO) and World Organisation for Animal Health (OIE)Geneva20064461
     [Google Scholar]
  5. GharebaghiN. SedokaniA. MehrnoM. A rare case of brucellosis with dermatomal pattern of cutaneous manifestation.Int. Med. Case Rep. J.20191222322810.2147/IMCRJ.S20368231372063
     [Google Scholar]
  6. Hasanjani RoushanM.R. EbrahimpourS. Human brucellosis: An overview.Caspian J. Intern. Med.201561464726221498
     [Google Scholar]
  7. ArizaJ. ServitjeO. PallarésR. Fernández ViladrichP. RufíG. PeyríJ. GudiolF. Characteristic cutaneous lesions in patients with brucellosis.Arch. Dermatol.1989125338038310.1001/archderm.1989.016701500700102923445
     [Google Scholar]
  8. KorkmazP. Doyuk KartalE. Skin manifestations associated with brucellosis.EMJ Dermatol201611912510.33590/emjdermatol/10312753
     [Google Scholar]
  9. ElbehiryA. AldubaibM. MarzoukE. AbalkhailA. AlmuzainiA.M. RawwayM. AlghamdiA. AlqarniA. AldawsariM. DrazA. The development of diagnostic and vaccine strategies for early detection and control of human brucellosis, particularly in endemic areas.Vaccines202311365410.3390/vaccines1103065436992237
     [Google Scholar]
  10. YagupskyP. MorataP. ColmeneroJ.D. Laboratory diagnosis of human brucellosis.Clin. Microbiol. Rev.2019331e00073-1910.1128/CMR.00073‑1931722888
     [Google Scholar]
  11. LiX. SunX. ZhangY. LuoS.X. YinH. ZhangH. WangZ. ChengZ. Human descending aorta injury caused by brucellosis: A case report.Medicine202310219e3376410.1097/MD.000000000003376437171302
     [Google Scholar]
  12. WillemsS.A. BrouwersJ.J.W.M. EeftingD. Aortic and iliac involvement in brucellosis : A rare but life threatening manifestation: A review of the literature.Eur. J. Vasc. Endovasc. Surg.202263574375010.1016/j.ejvs.2022.02.00435282998
     [Google Scholar]
  13. CastañoM.J. SoleraJ. Chronic brucellosis and persistence of brucella melitensis DNA.J. Clin. Microbiol.20094772084208910.1128/JCM.02159‑0819420176
     [Google Scholar]
  14. González-EspinozaG. Arce-GorvelV. MémetS. GorvelJ.P. Brucella: Reservoirs and niches in animals and humans.Pathogens202110218610.3390/pathogens1002018633572264
     [Google Scholar]
  15. Centers for disease control and prevention, brucellosis cdc yellow book 2024, travel-associated infections & diseases.2023Avaialble from:https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/
  16. DeanA.S. CrumpL. GreterH. SchellingE. ZinsstagJ. Global burden of human brucellosis: A systematic review of disease frequency.PLoS Negl. Trop. Dis.2012610e186510.1371/journal.pntd.000186523145195
     [Google Scholar]
  17. Centers for disease control and prevention.2012Avaialble from:https://www.cdc.gov/brucellosis/exposure/areas.html
  18. LaiS. ZhouH. XiongW. GilbertM. HuangZ. YuJ. YinW. WangL. ChenQ. LiY. MuD. ZengL. RenX. GengM. ZhangZ. CuiB. LiT. WangD. LiZ. WardropN.A. TatemA.J. YuH. Changing epidemiology of human brucellosis, China, 1955–2014.Emerg. Infect. Dis.201723218419410.3201/eid2302.15171028098531
     [Google Scholar]
  19. European Centre for Disease Prevention and ControlBrucellosis. In: ECDC. Annual epidemiological report for 2019. Stockholm: ECDC.2022Avaialble from: https://www.ecdc.europa.eu/sites/default/files/documents/BRUC_AER_2019.pdf
  20. ParaiD. SahooS.K. PattnaikM. SwainA. PeterA. SamantaL.J. PradhanR. ChoudharyH.R. NahakK.C. PatiS. BhattacharyaD. Seroprevalence of human brucellosis among the tribal and non-tribal population residing in an eastern state of India: Findings from the state-wide serosurvey.Front. Microbiol.202213107027610.3389/fmicb.2022.107027636519171
     [Google Scholar]
  21. KothalawalaK.A.C. MakitaK. KothalawalaH. JiffryA.M. KubotaS. KonoH. Association of farmers’ socio-economics with bovine brucellosis epidemiology in the dry zone of Sri Lanka.Prev. Vet. Med.201714711712310.1016/j.prevetmed.2017.08.01429254709
     [Google Scholar]
  22. FrancK.A. KrecekR.C. HäslerB.N. Arenas-GamboaA.M. Brucellosis remains a neglected disease in the developing world: A call for interdisciplinary action.BMC Public Health201818112510.1186/s12889‑017‑5016‑y29325516
     [Google Scholar]
  23. GiambartolomeiG.H. DelpinoM.V. Immunopathogenesis of hepatic brucellosis.Front. Cell. Infect. Microbiol.2019942310.3389/fcimb.2019.0042331956605
     [Google Scholar]
  24. MartirosyanA. MorenoE. GorvelJ.P. An evolutionary strategy for a stealthy intracellular Brucella pathogen.Immunol. Rev.2011240121123410.1111/j.1600‑065X.2010.00982.x21349096
     [Google Scholar]
  25. GrillóM.J. BlascoJ.M. GorvelJ.P. MoriyónI. MorenoE. What have we learned from brucellosis in the mouse model?Vet. Res.20124312910.1186/1297‑9716‑43‑2922500859
     [Google Scholar]
  26. López-SantiagoR. Sánchez-ArgáezA.B. De Alba-NúñezL.G. Baltierra-UribeS.L. Moreno-LafontM.C. Immune response to mucosal Brucella Infection.Front. Immunol.201910175910.3389/fimmu.2019.0175931481953
     [Google Scholar]
  27. Guzmán-VerriC. González-BarrientosR. Hernández-MoraG. MoralesJ.A. Baquero-CalvoE. Chaves-OlarteE. MorenoE. Brucella ceti and brucellosis in cetaceans.Front. Cell. Infect. Microbiol.20122310.3389/fcimb.2012.0000322919595
     [Google Scholar]
  28. CelliJ. The intracellular life cycle of Brucella spp.Microbiol. Spectr.2019727.2.0710.1128/microbiolspec.BAI‑0006‑201930848234
     [Google Scholar]
  29. StarrT. NgT.W. WehrlyT.D. KnodlerL.A. CelliJ. Brucella intracellular replication requires trafficking through the late endosomal/lysosomal compartment.Traffic20089567869410.1111/j.1600‑0854.2008.00718.x18266913
     [Google Scholar]
  30. von BargenK. GorvelJ.P. SalcedoS.P. Internal affairs: Investigating the Brucella intracellular lifestyle.FEMS Microbiol. Rev.201236353356210.1111/j.1574‑6976.2012.00334.x22373010
     [Google Scholar]
  31. PorteF. NaroeniA. Ouahrani-BettacheS. LiautardJ.P. Role of the Brucella suis lipopolysaccharide O antigen in phagosomal genesis and in inhibition of phagosome-lysosome fusion in murine macrophages.Infect. Immun.20037131481149010.1128/IAI.71.3.1481‑1490.200312595466
     [Google Scholar]
  32. HaagA.F. MykaK.K. ArnoldM.F.F. Caro-HernándezP. FergusonG.P. Importance of Lipopolysaccharide and Cyclic β -1,2-Glucans in Brucella -Mammalian Infections.Int. J. Microbiol.2010201011210.1155/2010/12450921151694
     [Google Scholar]
  33. AhmedW. ZhengK. LiuZ.F. Establishment of chronic infection: Brucella’s stealth strategy.Front. Cell. Infect. Microbiol.20166303010.3389/fcimb.2016.0003027014640
     [Google Scholar]
  34. ZhangG. LiangC. LiuC. ZhangJ. PiX. ZhangY. LiangX. WangL. ZhengB. Whole-genome sequence of brucella melitensis strain b7, isolated from a blood sample of a brucellosis patient from hulunbuir, inner mongolia, China.Microbiol. Resour. Announc.2019824e00119-1910.1128/MRA.00119‑1931196914
     [Google Scholar]
  35. PeiJ. Kahl-McDonaghM. FichtT.A. Brucella dissociation is essential for macrophage egress and bacterial dissemination.Front. Cell. Infect. Microbiol.201442310.3389/fcimb.2014.0002324634889
     [Google Scholar]
  36. HopH.T. ArayanL.T. HuyT.X.N. ReyesA.W.B. VuS.H. MinW. LeeH.J. RheeM.H. ChangH.H. KimS. The Key role of c-Fos for immune regulation and bacterial dissemination in brucella infected macrophage.Front. Cell. Infect. Microbiol.2018828710.3389/fcimb.2018.0028730186773
     [Google Scholar]
  37. AlaviS.M. AlaviL. Treatment of brucellosis: A systematic review of studies in recent twenty years.Caspian J. Intern. Med.20134263664124009951
     [Google Scholar]
  38. SkalskyK. YahavD. BisharaJ. PitlikS. LeiboviciL. PaulM. Treatment of human brucellosis: Systematic review and meta-analysis of randomised controlled trials.BMJ2008336764670170410.1136/bmj.39497.500903.2518321957
     [Google Scholar]
  39. PerkinsS.D. SmitherS.J. AtkinsH.S. Towards a Brucella vaccine for humans.FEMS Microbiol. Rev.201034337939410.1111/j.1574‑6976.2010.00211.x20180858
     [Google Scholar]
  40. Chacón-DíazC. Altamirano-SilvaP. González-EspinozaG. MedinaM.C. Alfaro-AlarcónA. Bouza-MoraL. Jiménez-RojasC. WongM. Barquero-CalvoE. RojasN. Guzmán-VerriC. MorenoE. Chaves-OlarteE. Brucella canis is an intracellular pathogen that induces a lower proinflammatory response than smooth zoonotic counterparts.Infect. Immun.201583124861487010.1128/IAI.00995‑1526438796
     [Google Scholar]
  41. GheibiA. KhanahmadH. KashfiK. SarmadiM. KhorramizadehM.R. Development of new generation of vaccines for Brucella abortus. Heliyon2018412e0107910.1016/j.heliyon.2018.e0107930603712
     [Google Scholar]
  42. DabralN. BurchamG.N. Jain-GuptaN. SriranganathanN. VemulapalliR. Overexpression of wbkF gene in Brucella abortus RB51WboA leads to increased O-polysaccharide expression and enhanced vaccine efficacy against B. abortus 2308, B. melitensis 16M, and B. suis 1330 in a murine brucellosis model.PLoS One2019143e021358710.1371/journal.pone.021358730856219
     [Google Scholar]
  43. O’CallaghanD. Human brucellosis: Recent advances and future challenges.Infect. Dis. Poverty20209110110.1186/s40249‑020‑00715‑132703319
     [Google Scholar]
  44. Avila-CalderónE.D. Lopez-MerinoA. SriranganathanN. BoyleS.M. Contreras-RodríguezA. A history of the development of Brucella vaccines.BioMed Res. Int.201320131810.1155/2013/74350923862154
     [Google Scholar]
  45. LalsiamtharaJ. LeeJ.H. Development and trial of vaccines against Brucella.J. Vet. Sci.201718S128129010.4142/jvs.2017.18.S1.28128859268
     [Google Scholar]
  46. PritamM. SinghG. SwaroopS. SinghA.K. PandeyB. SinghS.P. A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria.Int. J. Biol. Macromol.202015815917910.1016/j.ijbiomac.2020.04.19132360460
     [Google Scholar]
  47. KumarR. SrivastavaJ.K. SinghR. SiddiquiM.H. MansouriR.A. AbdulhakimJ.A. Bin-JumahM.N. AlkahtaniS. Abdel-DaimM.M. UddinM.S. Available compounds with therapeutic potential against COVID-19: Antimicrobial therapies, supportive care, and probable vaccines.Front. Pharmacol.20201158202510.3389/fphar.2020.58202533123014
     [Google Scholar]
  48. KhuranaS.K. SehrawatA. TiwariR. PrasadM. GulatiB. ShabbirM.Z. ChhabraR. KarthikK. PatelS.K. PathakM. Iqbal YatooM. GuptaV.K. DhamaK. SahR. ChaicumpaW. Bovine brucellosis : A comprehensive review.Vet. Q.2021411618810.1080/01652176.2020.186861633353489
     [Google Scholar]
  49. HansR. YadavP.K. SharmaP.K. BoopathiM. ThavaselvamD. Development and validation of immunoassay for whole cell detection of Brucella abortus and Brucella melitensis.Sci. Rep.2020101854310.1038/s41598‑020‑65347‑932444793
     [Google Scholar]
  50. LiZ. WangX. ZhuX. WangM. ChengH. LiD. LiuZ.G. Molecular characteristics of brucella isolates collected from humans in hainan province, china.Front. Microbiol.20201145210.3389/fmicb.2020.0045232292391
     [Google Scholar]
  51. YinD. LiL. SongX. LiH. WangJ. JuW. QuX. SongD. LiuY. MengX. CaoH. SongW. MengR. LiuJ. LiJ. XuK. A novel multi-epitope recombined protein for diagnosis of human brucellosis.BMC Infect. Dis.201616121910.1186/s12879‑016‑1552‑927206475
     [Google Scholar]
  52. HerrouJ. WillettJ.W. FiebigA. CzyżD.M. ChengJ.X. UlteeE. BriegelA. BigelowL. BabniggG. KimY. CrossonS. Brucella periplasmic protein EipB Is a molecular determinant of cell envelope integrity and virulence.J. Bacteriol.201920112e00134-1910.1128/JB.00134‑1930936371
     [Google Scholar]
  53. Kahl-McDonaghM.M. ElzerP.H. HagiusS.D. WalkerJ.V. PerryQ.L. SeaburyC.M. den HartighA.B. TsolisR.M. AdamsL.G. DavisD.S. FichtT.A. Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis.Vaccine200624245169517710.1016/j.vaccine.2006.04.00516697090
     [Google Scholar]
  54. Arenas-GamboaA.M. Rice-FichtA.C. FanY. Kahl-McDonaghM.M. FichtT.A. Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model.Clin. Vaccine Immunol.201219224926010.1128/CVI.05321‑1122169089
     [Google Scholar]
  55. PalmerM.V. OlsenS.C. ChevilleN.F. Safety and immunogenicity of Brucella abortus strain RB51 vaccine in pregnant cattle.Am. J. Vet. Res.19975854724779140553
     [Google Scholar]
  56. PonsartC. RiouM. LocatelliY. JacquesI. FadeauA. JayM. SimonR. PerrotL. FreddiL. BretonS. ChaumeilT. BlancB. OrtizK. VionC. RioultD. QuéméréE. SarradinP. CholletJ.Y. Garin-BastujiB. RossiS. Brucella melitensis Rev.1 vaccination generates a higher shedding risk of the vaccine strain in Alpine ibex (Capra ibex) compared to the domestic goat (Capra hircus).Vet. Res.201950110010.1186/s13567‑019‑0717‑031775863
     [Google Scholar]
  57. GuptaS. SinghD. GuptaM. BhatnagarR. A combined subunit vaccine comprising BP26, Omp25 and L7/L12 against brucellosis.Pathog. Dis.2019778ftaa00210.1093/femspd/ftaa00231971564
     [Google Scholar]
  58. CherwonogrodzkyJ.W. BarabéN.D. GrigatM.L. LeeW.E. PoirierR.T. JagerS.J. BergerB.J. Thermostable cross-protective subunit vaccine against Brucella species.Clin. Vaccine Immunol.201421121681168810.1128/CVI.00447‑1425320267
     [Google Scholar]
  59. KhademvatanS. SakiJ. KhajeddinN. Izadi-MazidiM. BeladiR. ShafieeB. SalehiZ. Toxoplasma gondii Exposure and the Risk of Schizophrenia.Jundishapur J. Microbiol.2014711e1277610.5812/jjm.1878925774275
     [Google Scholar]
  60. ZhuL. WangQ. WangY. XuY. PengD. HuangH. HuL. WeiK. ZhuR. Comparison of immune effects between Brucella recombinant Omp10-Omp28-L7/L12 proteins expressed in eukaryotic and prokaryotic systems.Front. Vet. Sci.2020757610.3389/fvets.2020.0057633195494
     [Google Scholar]
  61. CassataroJ. VelikovskyC.A. de la BarreraS. EsteinS.M. BrunoL. BowdenR. PasquevichK.A. FossatiC.A. GiambartolomeiG.H. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.Infect. Immun.200573106537654610.1128/IAI.73.10.6537‑6546.200516177328
     [Google Scholar]
  62. VelikovskyC.A. GoldbaumF.A. CassataroJ. EsteinS. BowdenR.A. BrunoL. FossatiC.A. GiambartolomeiG.H. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used.Infect. Immun.200371105750575510.1128/IAI.71.10.5750‑5755.200314500496
     [Google Scholar]
  63. PasquevichK.A. EsteinS.M. SamartinoC.G. ZwerdlingA. CoriaL.M. BarrionuevoP. FossatiC.A. GiambartolomeiG.H. CassataroJ. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.Infect. Immun.200977143644510.1128/IAI.01151‑0818981242
     [Google Scholar]
  64. Al-MaririA. TiborA. MertensP. De BolleX. MichelP. GodefroidJ. WalravensK. LetessonJ.J. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.Infect. Immun.20016984816482210.1128/IAI.69.8.4816‑4822.200111447155
     [Google Scholar]
  65. DelpinoM.V. MarchesiniM.I. EsteinS.M. ComerciD.J. CassataroJ. FossatiC.A. BaldiP.C. A bile salt hydrolase of Brucella abortus contributes to the establishment of a successful infection through the oral route in mice.Infect. Immun.200775129930510.1128/IAI.00952‑0617088355
     [Google Scholar]
  66. GómezL. LlanosJ. EscalonaE. SáezD. ÁlvarezF. MolinaR. FloresM. OñateA. Multivalent Fusion DNA Vaccine against Brucella abortus.BioMed Res. Int.201720171810.1155/2017/6535479
     [Google Scholar]
  67. BugybayevaD. KydyrbayevZ. ZininaN. AssanzhanovaN. YespembetovB. KozhamkulovY. ZakaryaK. RyskeldinovaS. TabynovK. A new candidate vaccine for human brucellosis based on influenza viral vectors: A preliminary investigation for the development of an immunization schedule in a guinea pig model.Infect. Dis. Poverty20211011310.1186/s40249‑021‑00801‑y33593447
     [Google Scholar]
  68. YangX. HudsonM. WaltersN. BargatzeR.F. PascualD.W. Selection of protective epitopes for Brucella melitensis by DNA vaccination.Infect. Immun.200573117297730310.1128/IAI.73.11.7297‑7303.200516239526
     [Google Scholar]
  69. OñateA.A. CéspedesS. CabreraA. RiversR. GonzálezA. MuñozC. FolchH. AndrewsE. A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice.Infect. Immun.20037194857486110.1128/IAI.71.9.4857‑4861.200312933826
     [Google Scholar]
  70. CommanderN.J. SpencerS.A. WrenB.W. MacMillanA.P. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes.Vaccine2007251435410.1016/j.vaccine.2006.07.04617049676
     [Google Scholar]
  71. SadeghiZ. Fasihi-RamandiM. BouzariS. Evaluation of immunogenicity of novel multi-epitope subunit vaccines in combination with poly I:C against Brucella melitensis and Brucella abortus infection.Int. Immunopharmacol.20197510582910582910.1016/j.intimp.2019.10582931437796
     [Google Scholar]
  72. VizcaínoN. CloeckaertA. DubrayG. ZygmuntM.S. Cloning, nucleotide sequence, and expression of the gene coding for a ribosome releasing factor-homologous protein of Brucella melitensis.Infect. Immun.199664114834483710.1128/iai.64.11.4834‑4837.19968890247
     [Google Scholar]
  73. MahmudA. KhanM.T. IqbalA. Identification of novel drug targets for humans and potential vaccine targets for cattle by subtractive genomic analysis of Brucella abortus strain 2308.Microb. Pathog.201913710373110373110.1016/j.micpath.2019.10373131509762
     [Google Scholar]
  74. RahmanN. ShahM. MuhammadI. KhanH. ImranM. Genome-wide core proteome analysis of brucella melitensis strains for potential drug target prediction.Mini Rev. Med. Chem.202121182778278710.2174/138955752066620070713334732634082
     [Google Scholar]
  75. OjoK.K. RanadeR.M. ZhangZ. DranowD.M. MyersJ.B. ChoiR. Nakazawa HewittS. EdwardsT.E. DaviesD.R. LorimerD. BoyleS.M. BarrettL.K. BucknerF.S. FanE. Van VoorhisW.C. Brucella melitensis methionyl-trna-synthetase (metrs), a potential drug target for brucellosis.PLoS One2016118e016035010.1371/journal.pone.016035027500735
     [Google Scholar]
  76. PradeepkiranJ.A. konidalaK. YellapuN. BhaskarM. Modeling, molecular dynamics, and docking assessment of transcription factor rho: A potential drug target in Brucella melitensis 16M.Drug Des. Devel. Ther.201591897191210.2147/DDDT.S7702025848225
     [Google Scholar]
  77. ThenR. Dihydropteroate synthase. xpharm.Comprehensive Pharmacology Reference, Elsevier.2007201717
     [Google Scholar]
  78. RaimondiM. RandazzoO. La FrancaM. BaroneG. VignoniE. RossiD. CollinaS. DHFR inhibitors: Reading the past for discovering novel anticancer agents.Molecules2019246114010.3390/molecules2406114030909399
     [Google Scholar]
  79. Paradis-BleauC. LloydA. SanschagrinF. ClarkeT. BlewettA. BuggT.D.H. LevesqueR.C. Phage display-derived inhibitor of the essential cell wall biosynthesis enzyme MurF.BMC Biochem.2008913310.1186/1471‑2091‑9‑3319099588
     [Google Scholar]
  80. AmeraG.M. KhanR.J. JhaR.K. PathakA. MuthukumaranJ. SinghA.K. Prioritization of Mur family drug targets against A. baumannii and identification of their homologous proteins through molecular phylogeny, primary sequence, and structural analysis.J. Genet. Eng. Biotechnol.20201813310.1186/s43141‑020‑00048‑432725318
     [Google Scholar]
  81. Salmon-DivonM. YeheskelA. KornspanD. Genomic analysis of the original Elberg Brucella melitensis Rev.1 vaccine strain reveals insights into virulence attenuation.Virulence2018911436144810.1080/21505594.2018.151167730139304
     [Google Scholar]
  82. ChangC.M. ChernJ. ChenM.Y. HuangK.F. ChenC.H. YangY.L. WuS.H. Avenaciolides: Potential mura-targeted inhibitors against peptidoglycan biosynthesis in methicillin-resistant staphylococcus aureus (MRSA).J. Am. Chem. Soc.2015137126727510.1021/ja510375f25521652
     [Google Scholar]
  83. ZhangF. GrahamJ. ZhaiT. LiuY. HuangZ. Discovery of mura inhibitors as novel antimicrobials through an integrated computational and experimental approach.Antibiotics202211452810.3390/antibiotics1104052835453279
     [Google Scholar]
  84. RaniJ. SillaY. BorahK. RamachandranS. BajpaiU. Repurposing of FDA-approved drugs to target MurB and MurE enzymes in Mycobacterium tuberculosis.J. Biomol. Struct. Dyn.20203892521253210.1080/07391102.2019.163728031244382
     [Google Scholar]
  85. AshrafB. AtiqN. KhanK. WadoodA. UddinR. Subtractive genomics profiling for potential drug targets identification against moraxella catarrhalis.PLoS One2022178e027325210.1371/journal.pone.027325236006987
     [Google Scholar]
  86. ChhabraG. DixitA. GargL.C. DNA polymerase III a subunit from Mycobacterium tuberculosis H37Rv: Homology modeling and molecular docking of its inhibitor.Bioinformation201162697310.6026/9732063000606921544168
     [Google Scholar]
  87. TarantinoP.M.Jr ZhiC. WrightG.E. BrownN.C. Inhibitors of DNA polymerase III as novel antimicrobial agents against gram-positive eubacteria.Antimicrob. Agents Chemother.19994381982198710.1128/AAC.43.8.198210428923
     [Google Scholar]
  88. AielloD. BarnesM.H. BiswasE.E. BiswasS.B. GuS. WilliamsJ.D. BowlinT.L. MoirD.T. Discovery, characterization and comparison of inhibitors of bacillus anthracis and staphylococcus aureus replicative DNA helicases.Bioorg. Med. Chem.200917134466447610.1016/j.bmc.2009.05.01419477652
     [Google Scholar]
  89. MaC. YangX. LewisP.J. Bacterial transcription as a target for antibacterial drug development.Microbiol. Mol. Biol. Rev.201680113916010.1128/MMBR.00055‑1526764017
     [Google Scholar]
  90. MandellZ.F. OshiroR.T. YakhninA.V. VishwakarmaR. KashlevM. KearnsD.B. BabitzkeP. NusG. NusG is an intrinsic transcription termination factor that stimulates motility and coordinates gene expression with NusA.eLife202110e6188010.7554/eLife.6188033835023
     [Google Scholar]
  91. O’NeillA.J. HuovinenT. FishwickC.W.G. ChopraI. Molecular genetic and structural modeling studies of staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence.Antimicrob. Agents Chemother.200650129830910.1128/AAC.50.1.298‑309.200616377701
     [Google Scholar]
  92. KimS. ChenJ. ChengT. GindulyteA. HeJ. HeS. LiQ. ShoemakerB.A. ThiessenP.A. YuB. ZaslavskyL. ZhangJ. BoltonE.E. PubChem 2023 update.Nucleic Acids Res.202351D1D1373D138010.1093/nar/gkac95636305812
     [Google Scholar]
  93. WishartD.S. FeunangY.D. GuoA.C. LoE.J. MarcuA. GrantJ.R. SajedT. JohnsonD. LiC. SayeedaZ. AssempourN. IynkkaranI. LiuY. MaciejewskiA. GaleN. WilsonA. ChinL. CummingsR. LeD. PonA. KnoxC. WilsonM. DrugBank 5.0: A major update to the DrugBank database for 2018.Nucleic Acids Res.201846D1D1074D108210.1093/nar/gkx103729126136
     [Google Scholar]
/content/journals/cmp/10.2174/1874467217666230713093802
Loading
Pathophysiology, Current Therapeutic Options, Vaccine Candidates, and Drug Targets for Human Brucellosis
Curr Mol Pharmacol 17, e130723218680 (2024); https://doi.org/10.2174/1874467217666230713093802
/content/journals/cmp/10.2174/1874467217666230713093802
/content/journals/cmp/10.2174/1874467217666230713093802
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Brucellosis; Drug target; Inhibition of apoptosis; Pathophysiology; Rose Bengal test (RBT); Vaccine candidate

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test